ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFMS
CUSIPN/A
Phone781-345-9001
Debt
Debt-to-Equity Ratio0.49
Current Ratio5.95
Quick Ratio5.34
Price-To-Earnings
Trailing P/E Ratio-0.83
Forward P/E Ratio-1.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$78.11 million
Price / Sales0.80
Cash FlowN/A
Price / CashN/A
Book Value$1.02 per share
Price / Book1.01
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-53,580,000.00
Net Margins-62.63%
Return on Equity-83.49%
Return on Assets-46.31%
Miscellaneous
Employees350
Outstanding Shares60,910,000
Market Cap$62.74
ConforMIS (NASDAQ:CFMS) Frequently Asked Questions
What is ConforMIS's stock symbol?
ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."
How were ConforMIS's earnings last quarter?
ConforMIS Inc (NASDAQ:CFMS) issued its quarterly earnings results on Wednesday, May, 2nd. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.03. The medical instruments supplier earned $19.66 million during the quarter, compared to the consensus estimate of $19.51 million. ConforMIS had a negative return on equity of 83.49% and a negative net margin of 62.63%. View ConforMIS's Earnings History.
When is ConforMIS's next earnings date?
What price target have analysts set for CFMS?
7 brokers have issued 1-year price objectives for ConforMIS's stock. Their predictions range from $3.00 to $5.00. On average, they expect ConforMIS's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 288.3% from the stock's current price. View Analyst Ratings for ConforMIS.
What is the consensus analysts' recommendation for ConforMIS?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting ConforMIS?
ConforMIS saw a drop in short interest in June. As of June 29th, there was short interest totalling 1,454,157 shares, a drop of 53.9% from the June 15th total of 3,151,933 shares. Based on an average daily volume of 786,873 shares, the short-interest ratio is currently 1.8 days. Currently, 2.9% of the company's shares are sold short. View ConforMIS's Current Options Chain.
Who are some of ConforMIS's key competitors?
Who are ConforMIS's key executives?
ConforMIS's management team includes the folowing people:
- Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)
- Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)
- Dr. Daniel Steines M.D., MS, Chief Technology Officer (Age 49)
- Mr. Ed Kilgallen, VP of Operations
- Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52)
When did ConforMIS IPO?
(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.
Has ConforMIS been receiving favorable news coverage?
Press coverage about CFMS stock has been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ConforMIS earned a daily sentiment score of 0.13 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.08 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of ConforMIS?
Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ConforMIS's stock price today?
One share of CFMS stock can currently be purchased for approximately $1.03.
How big of a company is ConforMIS?
ConforMIS has a market capitalization of $62.74 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe.
How can I contact ConforMIS?
ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]
MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)
MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
